Achilles Therapeutics plc (ACHL)

NASDAQ: ACHL · IEX Real-Time Price · USD
1.250
+0.040 (3.31%)
At close: Mar 28, 2024, 4:00 PM
1.270
+0.020 (1.60%)
After-hours: Mar 28, 2024, 7:39 PM EDT

Company Description

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors.

The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma.

The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021.

Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.

Achilles Therapeutics plc
Achilles Therapeutics logo
Country United Kingdom
Founded 2016
IPO Date Mar 31, 2021
Industry Biotechnology
Sector Healthcare
Employees 234
CEO Dr. Iraj Ali Ph.D.

Contact Details

Address:
245 Hammersmith Road
London, X0 W6 8PW
United Kingdom
Phone 44 (0)20 8154 4600
Website achillestx.com

Stock Details

Ticker Symbol ACHL
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $18.00
CIK Code 0001830749
CUSIP Number 00449L102
ISIN Number US00449L1026
SIC Code 2836

Key Executives

Name Position
Dr. Iraj Ali Ph.D. Chief Executive Officer and Director
Dr. Karl Stuart Peggs M.D. Founder and Chief Medical Officer
Dr. Mark William Lowdell BSc, FRCPath, MICR, MSc, Ph.D. Founder
Dr. Charles Swanton FMEDSCI, M.D., Ph.D. Founder
Dr. Sergio A. Quezada Ph.D. Founder and Chief Scientific Officer
Robert Coutts Chief Financial Officer
Lee M. Stern Vice President of Investor Relations and External Communications
Daniel Carey Cazel Hood General Counsel and Company Secretary
Julia Wilson Head of Communications
Tariq Ahmed Executive Vice President of People

Latest SEC Filings

Date Type Title
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 1, 2024 144 Filing
Nov 13, 2023 6-K Report of foreign issuer
Nov 1, 2023 144 Filing
Sep 22, 2023 6-K Report of foreign issuer
Aug 17, 2023 144 Filing
Aug 4, 2023 6-K Report of foreign issuer
Jun 29, 2023 6-K Report of foreign issuer
May 10, 2023 6-K Report of foreign issuer